Innovative Non-Opioid Molecule Provides Long-Lasting Pain Relief

Researchers from the University at Buffalo have developed a novel molecule that functions similarly to a local anesthetic, delivering sustained pain relief for up to three weeks. This groundbreaking preclinical study, recently published in the journal Pain, indicates potential for a new class of non-opioid pain medications. Unlike traditional anesthetics used during dental or surgical procedures, this molecule is designed to target specific pain pathways, minimizing side effects and increasing duration of relief.

The molecule operates by acting on a protein called Magi-1, which organizes communication channels related to pain transmission within nerve cells. Specifically, it interacts with the NaV1.8 ion channel, a critical component in transmitting pain signals. Instead of blocking the channel altogether—the approach of some previous drugs—the new compound disrupts its interaction with Magi-1. This decoy mechanism prompts the degradation of NaV1.8 channels, reducing their ability to send pain signals.

The lipidation process of this peptide allows it to anchor firmly within neuronal membranes, protecting it from enzymes that could break it down. As a result, a single injection can lead to prolonged pain relief, making it a promising candidate for chronic pain management. The research team, led by Professor Arin Bhattacharjee, is now exploring the application of this technology in humans, with plans to begin toxicity trials.

While a similar drug that blocks NaV1.8 channels has been approved for acute pain, it has not proven effective for chronic conditions. This new approach targets the scaffolding interaction, offering hope for patients suffering from long-term pain without the risks associated with opioids. The team is actively seeking partnerships to advance this promising therapy into clinical trials.

Source: https://medicalxpress.com/news/2025-06-opioid-molecule-anesthetic-relieving-chronic.html